GALT - Galectin Therapeutics Inc

GALT - Galectin Therapeutics Inc

https://galectintherapeutics.com

Recent News

Powered by Alpha Vantage

Galectin Therapeutics Inc. ( GALT ) Is Up 7.48% in One Week: What You Should Know

Zacks Commentary • 2 days, 23 hours ago • score: 0.40

Does Galectin Therapeutics Inc. (GALT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Is ANI Pharmaceuticals ( ANIP ) Stock Outpacing Its Medical Peers This Year?

Zacks Commentary • 5 months, 1 week ago • score: 0.33

Here is how ANI Pharmaceuticals (ANIP) and Galectin Therapeutics Inc. (GALT) have performed compared to their sector so far this year.

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference - Galectin Therapeutics ( NASDAQ:GALT )

Benzinga • 8 months ago • score: 0.29

NORCROSS, Ga., Jan. 10, 2025 ( GLOBE NEWSWIRE ) -- Galectin Therapeutics, Inc.

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

GlobeNewswire • 8 months ago • score: 0.29

NORCROSS, Ga., Jan. 10, 2025 ( GLOBE NEWSWIRE ) -- Galectin Therapeutics, Inc. ( NASDAQ: GALT ) , the leading developer of therapeutics that target galectin proteins, today announced that the top-line results of the NAVIGATE trial in patients with MASH cirrhosis and portal hypertension will be ...

Why Is Small Cap Galectin Therapeutics Stock Trading Lower On Friday? - Galectin Therapeutics ( NASDAQ:GALT )

Benzinga • 8 months, 3 weeks ago

NAVIGATE trial reduced varices by 43.2% in the belapectin 2 mg/kg group, but didn't reach statistical significance. Galectin expects further data from 50 patients treated for 36 months in early 2025. On Friday, Galectin Therapeutics, Inc.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the research and development of therapies for fibrotic, cancerous and other diseases. The company is headquartered in Norcross, Georgia.

52W High

$4.71

52W Low

$0.73

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

0.87

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-4.04

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

207.70

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

30.08%

Institutions (25–75% balanced)

16.46%

Shares Outstanding

64,060,000

Float

44,925,500

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

0

Gross Profit (TTM)

0

EPS (TTM)

-0.64

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-37.28%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Value

N/A

Previous

N/A

Trend

—

Signal Cross

No cross

As of

—